Enterprise to host convention simply call and webcast at 8:30 a.m. EDT
CARMIEL, Israel, March 22, 2021 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical corporation concentrated on the growth, generation and commercialization of recombinant therapeutic proteins generated by its proprietary ProCellEx® plant mobile-dependent protein expression method, nowadays announced that it will launch its money outcomes for fiscal yr 2020 and business update on Tuesday, March 30, 2021. The Company’s administration will host a conference call to talk about the economic success and give a business update on modern corporate and medical developments at 8:30 a.m. Japanese Daylight Time (EDT).
Convention Simply call Information:
Tuesday, March 30, 2021, 8:30 a.m. Japanese Daylight Time (EDT)
Domestic: 1-877-413-2408
Intercontinental: 201-689-8573
Meeting ID: 13716316
The meeting simply call will be webcast live from the Firm’s web site and will be out there by way of the pursuing backlinks:
Webcast Particulars:
Enterprise Url: https://protalixbiotherapeutics.gcs-world wide web.com/events0
Webcast Url: https://tinyurl.com/hz84rysc
Meeting ID: 13716316
Make sure you obtain the web-sites at minimum 15 minutes in advance of the meeting to sign up, download and install any required audio computer software.
The meeting connect with will be accessible for replay for two weeks on the Events Calendar of the Traders part of the Firm’s internet site, at the above hyperlink.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical corporation concentrated on the enhancement and commercialization of recombinant therapeutic proteins expressed via its proprietary plant mobile-based mostly expression technique, ProCellEx®. Protalix was the very first corporation to obtain U.S. Foodstuff and Drug Administration (Food and drug administration) acceptance of a protein generated by plant cell-based mostly in suspension expression system. Protalix’s unique expression method signifies a new approach for acquiring recombinant proteins in an industrial-scale way.
Protalix’s initial merchandise manufactured by ProCellEx, taliglucerase alfa, was accepted for advertising and marketing by the Food and drug administration in Might 2012 and, subsequently, by the regulatory authorities of other nations. Protalix has accredited to Pfizer Inc. the around the globe growth and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix’s improvement pipeline consists of proprietary versions of recombinant therapeutic proteins that target set up pharmaceutical markets, together with the adhering to products candidates: pegunigalsidase alfa, a modified model of the recombinant human α-Galactosidase-A protein for the proposed procedure of Fabry illness alidornase alfa or PRX-110, for the procedure of many human respiratory illnesses or circumstances PRX-115, a plant cell-expressed recombinant PEGylated uricase for the cure of refractory gout PRX-119, a plant mobile-expressed extensive action DNase I for the therapy of NETs-similar ailments and other people. Protalix has partnered with Chiesi Farmaceutici S.p.A., the two in the United States and outdoors the United States, for the growth and commercialization of pegunigalsidase alfa, and with SarcoMed United states of america, Inc. for the throughout the world development and commercialization of PRX-110 for use in the procedure of any human respiratory condition or affliction like, but not confined to, sarcoidosis, pulmonary fibrosis, and other similar health conditions by way of inhaled delivery.
Investor Call
Chuck Padala, Running Director
LifeSci Advisors
646-627-8390
[email protected]
Watch primary material:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-hold-fiscal-calendar year-2020-economical-and-small business-benefits-meeting-call-on-march-30-2021-301252732.html
Source Protalix BioTherapeutics, Inc.
